Executive Summary
Synairgen plc was founded by Professors Stephen Holgate, Donna Davies and Ratko Djukanovic, a world-renowned respiratory research team from the University of Southampton, and spun-out from the University in June 2003. Synairgen seeks to commercialise a number of drug discovery opportunities, through its own internal research programmes and those that have been carefully selected from the wider range of research projects led by the Founders in their academic roles, and which offer out-licensing opportunities. The Group intends to out-license its IP at an early stage (pre-Phase II) rather than committing significant capital resources to late-stage clinical trials. Since June 2003, the Company has made significant progress: two proprietary programmes in the field of asthma have been initiated and the Company has signed four agreements with pharmaceutical and biotechnology companies, including Merck Frosst (affiliate of Merck & Co Inc), Cambridge Antibody Technology and Centocor Inc (part of Johnson and Johnson). Synairgen is currently discussing further collaboration agreements.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
